Advertisement
Organisation › Details
CSL (Group)
CSL (ASX: CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus- provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest *
Start | 1997-08-29 existent | |
End | 1997-08-29 existent | |
Today | CSL Ltd. (ASX: CSL, USOTC:CSLLY) | |
Industry | pharmaceutical | |
Region | Australia_oooo | |
Country | Australia | |
Street | 45 Poplar Road | |
City | 3052 Parkville VIC | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | H: 10,001 to 50,00 (2021-12-14) |
* Document for »About Section«: Vifor Pharma AG. (12/14/21). "Press Release: CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd (ad hoc)". St. Gallen. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for CSL (Group)
- [1] Helmore, Edward [The Guardian]. (11/23/22). "News: Gene Therapy at $3.5m a Dose Approved for US Adults with Hemophilia B"....
- [2] Vifor Pharma AG. (12/14/21). "Press Release: CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd (ad hoc)". St. Gallen....
- [3] Uniqure N.V.. (12/9/21). "Press Release: Uniqure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B". Lexington, MA, Amsterdam & King of Prussia, PA....
- [4] Thermo Fisher Scientific Inc.. (9/23/21). "Press Release: Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland". Bremen....
- [5] Uniqure N.V.. (6/24/20). "Press Release: Uniqure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy". Lexington, MA & Amsterdam....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top